Session 4_May21_Prework Flashcards

Colorectal Cancer and Pancreatic Cancer (31 cards)

1
Q

When would you expect acute side effects to H&N radiation to start developing?

A

2-4 weeks after initiation of radiation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

When would you expect acute side effects to H&N radiation to hit its peak?

A

Right at the completion of Radiation therapy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

When would you expect acute side effects to H&N radiation to start getting better?

A

1-3 weeks after radiation is completed

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

For radiation to treat bone pain, when would you expect pain to improve?

A

2 weeks to 2 months later

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What is maintenance therapy?

A

is usually long-term and aims to sustain disease control and prolong survival. So this doesn’t always mean the cancer is gone - but maybe it’s stable, and the goal here is to keep it stable.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What is adjuvant therapy?

A

Treatment given after surgical intervention.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What is neoadjuvant therapy?

A

Treatment given before surgical intervention.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

IO

A

Immuno-oncology, Immunotherapy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

PD-1 and CTLA-4

A

Examples of immune checkpoints, expressed on T-cells

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Immune Checkpoints

A

Regulatory proteins (PD-1, CTLA-4) which, when bound to corresponding ligand on another tissue (ie cancer), turns off the immune response.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Immune checkpoint inhibitors

A

Type of immunotherapy that blocks immune checkpoints, allowing T-cells to recognize and attack cancer cells. Enhances anti-tumor immune response.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Differentiate between immunotherapy and targeted therapy.

A

Immunotherapy exploits the patient’s immune system to fight cancer, while targeted therapy targets specific molecules or pathways in the cancerous tissue.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What is targeted therapy?

A

Small molecule inhibitor that go inside the cancer cell to block oncogenes that are essential for tumor proliferation or survival.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

If a patient will respond to targeted therapies, how quickly might they start noticing an improvement?

A

Days to weeks

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

If a patient will respond to immune checkpoint inhibitors, how quickly might you notice an improvement?

A

weeks to months

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What does oligometastatic mean?

A

The cancer has metastasized to 1 or 2 organs and the lesions are discreet and easy to target.

17
Q

What does FOLFOX refer to?

A

First line chemotherapy for metastatic Colorectal cancer

18
Q

What are common side effects of Oxaliplatin?

A

the OX in FOLFOX: Oxaliplatin has distinct side effects including neuropathy and temperature sensitivity.

19
Q

What does it mean to be RAS (or BRAF) Wildtype?

A

Meaning the cancer doesn’t have any mutations to it

20
Q

When a patient with metastatic NSCLC has a targetable mutation, does it improve or worsen prognosis?

A

It improves prognosis

21
Q

What does dMMR stand for?

A

Mismatch Repair deficient

22
Q

What does pMMR stand for?

A

Mismatch Repair proficient

23
Q

What does MSI-H stand for?

A

Microsatellite Instability - High

24
Q

What does MSS stand for?

A

Microsatellite Stable

25
What are the positive prognostic markers for metastatic colorectal cancer?
If It's oligometastatic with easy to treat metastases, if cancer is RAS/BRAF wildtype, if cancer is dMMR/MSI-H
26
What is Cetuximab?
an EGFR antibody.
27
How is Cetuximab different from targeted therapies such as Osimertinib?
Cetuximab is an antibody to EGFR that blocks EGFR pathway from the outside. Osimertinib is a small molecule that invade the cancer cell and finds the very specific mutation to block.
28
If a patient has a rash from cetuximab, how does that impact their prognosis/response?
It can be an indicator that the right cells are being targeted and that it can improve response and overall survival.
29
What is prognosis for a patient who is diagnosed with locally advanced pancreatic cancer?
1-2 years
30
What is prognosis for a patient who is diagnosed with metastatic pancreatic cancer?
8-11 months
31
What is EGFR?
A proto-oncogene. A protein that is present in all tissues in the body (healthy and cancerous). It plays a role in regulating cell proliferation and survival.